| Thursday, May 14, 2009 |
| 02:49 PM |
|
Eli Lilly (NYSE: LLY) CEO Opines Cost Effectiveness Stifles Innovation
Published by clickbroker.blogspot.com Pharmaceutical giant Eli Lilly & Co. (LLY) CEO John C. Lechleiter’s Wall Street Journal opinion <a [More...]
|
home: iStockAnalyst....
|
| Wednesday, May 06, 2009 |
| 11:29 AM |
|
Company News Briefs: Garmin, Foster Wheeler, Agrium Miss Targets
Garmin (GRMN) reported first quarter earnings of 25 cents a share, a 17 cent miss, as revenues declined 34.2% year-over-year to $437 million
Agrium (AGU) reported first-quarter earnings of 4 cents a share, a 20 cent miss, as revenues jumped 58.4% year-over year to $1.75 billion. The Company said it expects second ...
|
Daily Markets
|
| Tuesday, May 05, 2009 |
| 10:35 PM |
|
Google, Apple Under Antitrust Scanner
Against the backdrop of a possible launch of Microsoft Corp.’s (MSFT) new smartphone, federal regulators are now investigating if an overlap of directors on the boards of Apple Inc. (AAPL) and Google Inc. (GOOG) breach antitrust laws.
The Silicon Valley giants share two directors on their boards, Eric Schmidt, chief executive of ...
|
Daily Markets
|
| Wednesday, April 29, 2009 |
| 06:23 PM |
|
Sequenom (Nasdaq: SQNM) Bombshell
I am saying "wow" a lot of late - Sequenom (SQNM) is out with something after hours I've never seen in all the years I've been doing stocks; a delay in their Down Syndrome test due to employee mishandling of data. The stock is down 50% after hours. Worse - this was our only long position I actually have a hedge against, but I covered it into the weakness early this week - basically have 50 shares short as a holding position. On the long side we only have a 1.4% stake since the stock chart has been awful but looks like that will be 0.7% by tomorrow. Not good - it's one thing to be hit by an earnings situation but this is out of left field. Here I thought this was my personal Dendreon (DNDN) - something I'd stick with in the long run, waiting for the magical day to arrive it goes up 200% in a session. Well, we will see what [More...]
|
home: iStockAnalyst....
|
| Wednesday, April 22, 2009 |
| 04:00 AM |
|
The Next Millionaire-Maker Megatrend
Bigger than the Internet by an order of magnitude.
|
Fool.com Headlines
|
| Tuesday, April 21, 2009 |
| 09:54 AM |
|
Who’s Next to Pay a Dividend?
Back in August, we put together a list of companies on Dividend.com that I would love to see dividend payouts from. Here is a snapshot of the bulk of the list.
Amazon (AMZN)
Amgen (AMGN)
Apple (AAPL)
Bed Bath & Beyond (BBBY)
Berkshire Hathaway (BRK-A)
Celgene (CELG) Cisco Systems (CSCO) Coach (COH)- got the word today.
Dell (DELL)
DirecTV (DTV)
Ebay (EBAY)
Electronic Arts (ERTS)
EMC [...]
|
Dividend Stocks - Th...
|
| Thursday, April 16, 2009 |
| 04:54 PM |
|
Biotech Industry - Industry Outlook
Last year, the Biotech industry as a whole achieved a much better performance than the market. Both the NASDAQ Biotech Index and AMEX Biotech Index outperformed all three major market indices (Dow Jones Industrial Average, NASDAQ Composite and S&P 500) in a large margin. The major indices declined as much as 40% while the NASDAQ Biotech Index declined only 12.6% and the AMEX Biotech Index was down 17.7%. However, when the recession enters into its third year, the Biotech industry is not doing better than the market, which has been evident by the indices' performances. As of April 9, 2009, AMEX Biotech Index declined 3%, and the broader NASDAQ Biotech Index was down 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over 130 component companies). Although the Dow and S&P 500 also declined a similar percentage, technology-laden NASDAQ actually has a gain of 4.8%, which is more comparable to the biotech indices. See [More...]
|
home: iStockAnalyst....
|
| Tuesday, April 14, 2009 |
| 11:31 AM |
|
U.S. Economy Still Weak but Improving
While many analysts expect U.S. corporate earnings and overall economic data to remain weak by historical standards, there may well be enough of an improvement over the prior months and quarters to spark some optimism that there are better times ahead.
For instance, a 5% to 6% contraction in first quarter…
|
Jutia Group
|
| 08:59 AM |
|
After A Tough First Quarter, Investors Have Cause For Cautious Optimism
While many analysts expect U.S. corporate earnings and overall economic data to remain weak by historical standards, there may well be enough of an improvement over the prior months and quarters to spark some optimism that there are better times ahead. [More...]
|
home: iStockAnalyst....
|
| Monday, April 13, 2009 |
| 01:56 PM |
|
Highly Defensive Index: Opportunities In Healthcare
The ETF Innovators Highly Defensive Index contains 32 market cap leading companies from the defensive industry groups (A-K) specified below in addition to one position reserved for the SPDR Gold Trust (GLD) as a hedge against long-term inflation and global currency devaluation. Since I last wrote about the index two months ago, Genentech has been acquired by Roche (RHHBY.PK) and the number of securities has been reduced from 40 to 33. Over the past year, the index has outpaced the over (...) [More...]
|
home: iStockAnalyst....
|
| Wednesday, April 08, 2009 |
| 05:08 PM |
|
Genentech (DNA) Announces Voluntary Withdrawal of Raptiva from the U.S. Market
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=4550964 for the full story.
|
StreetInsider
|
| 04:30 PM |
|
Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market
|
Business Wire
|
| Saturday, March 28, 2009 |
| 03:00 AM |
|
Technical Trade Alert on Market Movers: YGE, DPS, CAG, RSH, FCS, DNA
|
EmailWire.Com Press ...
|
| Friday, March 27, 2009 |
| 11:54 AM |
|
Moody's Cuts Roche To 'A2' Following Genentech Tender Offer
Moody's Cuts Roche To 'A2' Following Genentech Tender Offer 
|
FOXBusiness.com
|
| 10:52 AM |
|
Moody's Downgraded Rating On Roche Following Genentech Buyout
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=4517865 for the full story.
|
StreetInsider
|
| Thursday, March 26, 2009 |
| 01:07 PM |
|
Roche Completes Acquisition of Genentech (DNA)
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=4515505 for the full story.
|
StreetInsider
|
| 01:03 PM |
|
Roche Completes Acquisition of Genentech
|
PR Newswire
|
| 10:14 AM |
|
The Best Way to Fund Your Retirement
Choose the right strategy to pay for your golden years.
|
Fool.com Headlines
|
| 02:00 AM |
|
Roche Completes Tender Offer for Genentech
|
PR Newswire
|
| Wednesday, March 25, 2009 |
| 04:33 PM |
|
Spring Brings 'Green Shoots' For Stocks
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=4513302 for the full story.
|
StreetInsider
|
| |
More All For DNA
|
|